Financial Firms Adjust Amgen Stock Ratings Following Revenue Appraisals
Wednesday / 05/20/2026, 20:20 EST
Piper Sandler cut Amgen's price target to $427 while keeping an Overweight rating, citing rare disease drug growth. Freedom Broker upgraded the stock to Buy with a $375 target after Q1 decline.
